Alexander A. Vinks, PharmD, PhD, FCP
Title
Director, Pediatric Pharmacology Research Unit
Appointment
Professor of Pediatrics; Adjunct Professor of Pharmacology
Email
sander.vinks@cchmc.org
Phone
513-636-0159
Fax
513-636-0168
Bio
Dr. Vinks received his MS in Pharmacology from the University of Toronto, Canada and a Pharmacy degree and PhD in Pharmacology from Leiden University, The Netherlands. He was trained as a hospital pharmacist (PharmD) and clinical pharmacologist at The Hague Hospitals Central Pharmacy, The Hague, The Netherlands.
Before joining the Division of Pharmacology Research at Cincinnati Children's Hospital Medical Center, he was Director of the Clinical Pharmacology & Toxicology Laboratory at The Hague. Dr. Vinks has spent over 20 years in the field of Therapeutic Drug Monitoring and applied pharmacokinetics, both in the research aspects of population pharmacokinetic studies, as well as in the clinical application of these approaches to clinical patient care.
Dr. Vinks holds an academic appointment with the University of Cincinnati Collegeof Medicine and is the Principal Investigator for the Pediatric Pharmacology Research Unit (PPRU). He is director of the Laboratory of Applied Pharmacokinetics and Therapeutic Drug Management (LAP/TDM) and clinical pharmacology fellowship program at Cincinnati Children's. His current research interests include pharmacokinetic-pharmacodynamic (PK-PD) modeling and the application of population and simulation methods in TDM and clinical trial design. He has authored over 50 publications in the area of TDM, pharmacokinetics and clinical pharmacology. Dr. Vinks has been actively involved with International Association of Therapeutic Drug Monitoring and Clinical Toxicology from the beginning. He is chair of the TDM cost-effectiveness committee, serves as Secretary of the Executive Board of Directors, and is on the Editorial Board of the journal Therapeutic Drug Monitoring. Dr. Vinks is both board certified in clinical pharmacology and toxicology and is a fellow of the American College of Clinical Pharmacology.
Dr. Vinks' Profile
Dr. Vinks was profiled in the Summer 2005 issue of Research Horizons. You can read the article, Developing Computer Models for Personalized Drug Dosing to learn more about some of his research.
Credentials
Certification American Board of Clinical Pharmacology, 2001
PhD Clinical Pharmacology, Leiden University, Leiden The Netherlands, 1996
PharmD Hospital Pharmacy, The Hague Central Hospital Pharmacy, The Hague, The Netherlands, 1986
MS Pharmacology, University of Toronto, Toronto Canada, 1983
MS Pharmacy, Leiden University, Leiden, The Netherlands, 1982
Awards and Honors
1982 Graduation with honors: Leiden University
1991 Vice president, Dutch Society of Hospital Pharmacists.
1993 Board Certification Clinical Pharmacology
(Netherlands)
Sanofi Wintrop best publication award
Board Certification Toxicology (European Community)
1999 Huizinga Outstanding Hospital Pharmacy Research Award
1999 Director of Education, International Association for Therapeutic Drug Monitoring and Clinical Toxicology.
2002 Fellow, American College of Clinical Pharmacology
2003 Secretary Executive Board, International Association for Therapeutic Drug Monitoring and Clinical Toxicology
2004 Chair, Therapeutic Drug and Toxicology Monitoring Committee, American Society for Clinical Pharmacology and Toxicology
2006 ASCPT (American Society for Clinical Pharmacology and Therapeutics) Member of the Month, September
Research Grants and Contracts
2U10HD37249-06, NICHD, 01/01/04 – 12/31/09
Pediatric Pharmacology Research Unit (PPRU)
The major goals of this project are to study drug action and disposition in infants and children and provide the clinical data necessary for new drug approval and better and safer use of drugs in children.
Role: Principal investigator
U01 HD037249-04S, NICHD, 9/30/02-31/08/04
Risperidone Pharmacogenetics in Children with pervasive Developmental Disorder (PDD)
The major goals of this project are to study influence of genetic polymorphisms of drug metabolizing enzymes (CYP2D6 and CYP 3A4) and drug receptors (DR1, DR4, 5HT) on risperidone pharmacokinetics, response and adverse events profiles in children with PDD.
Role: Principal investigator
R21 HD42440 -01, NICHD, 9/15/01-31/08/04
Risperidone Pharmacokinetics in Children with pervasive Developmental Disorder (PDD)
The major goals of this project are to establish novel sensitive low volume assay methodology and generate population pharmacokinetic data for risperidone to be used in dose optimization.
Role: Principal investigator
U18 HS10397-04, AHRQ, 9/30/99-9/29/07
University of North Caroline Center for Education and Research on Therapeutics Competitive Continuation: Rational Therapeutics for the Pediatric Population. The major goals of this project are to improve therapeutic use in the pediatric population through research and education. Our project within the CERT is "Development of Model Pediatric Therapeutic Drug Monitoring Services" which evaluates current TDM practices at three different pediatric institutions in order to develop better tools and teaching materials to improve TDM usage.
Role: Co-Investigator and Project Leader
Publications, Most Recent
Mehta P, Vinks A, Filipovich A, Vaughn G, Fearing D, Sper C, Davies S. (in press) Pharmacokinetics of High-Dose Weekly Ambisome (liposomal amphotericin B) Anti-Fungal Prophylaxis in Pediatric Bone Marrow Transplant (BMT) Patients.Biology of Blood and Marrow Transplantation.
Touw DJ, Neef C, Thomson AH, Vinks AA. (2005) Cost-effectiveness of therapeutic drug monitoring: a systematic review.Ther Drug Monit 27:10-7.
Mouton JW, Punt N, Vinks AA. (2005) A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.Clin Ther 27:762-72.
Mouton JW, Vinks AA. (2005) Relationship between minimum inhibitory concentration and stationary concentration revisited: growth rates and minimum bactericidal concentrations.Clin Pharmacokinet 44:767-8.
Mouton JW, Vinks AA. (2005) Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration.Clin Pharmacokinet 44:201-10.
de Wildt SN, de Hoog M, Vinks AA, Joosten KF, van Dijk M, van den Anker JN. (2005) Pharmacodynamics of midazolam in pediatric intensive care patients.Ther Drug Monit 27:98-102.
Carlsson KC, Hoem NO, Glauser T, Vinks AA. (2005) Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.Clin Ther 27:618-26.
Williams MT, Brown CA, Skelton MR, Vinks AA, Vorhees CV. (2004) Absorption and clearance of +/-3,4-methylenedioxymethamphetamine from the plasma of neonatal rats.Neurotoxicol Teratol 26:849-56.
Bos AM, Boom K, Vinks AA, Boezen HM, Wanders J, Dombernovsky P, Aamdal S, de Vries EG, Uges DR. (2004) Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755.Cancer Chemother Pharmacol 54:64-70.
Sallee FR, Gilbert DL, Vinks AA, Miceli JJ, Robarge L, Wilner K. (2003) Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission.J Am Acad Child Adolesc Psychiatry 42:902-7.
Vinks AA, Den Hollander JG, Overbeek SE, Jelliffe RW, Mouton JW. Population Pharmacokinetic Analysis of Nonlinear Behavior of Piperacillin during Intermittent or Continuous Infusion in Patients with Cystic Fibrosis.Antimicrobial Agents Chemotherapy 2003;47(2):541-547.
Sallee FR, Gilbert DL, Vinks AA, Miceli JJ, Robarge L, Wilner K. Pharmacodynamics of Ziprasidone in Children and Adolescents: Impact on Dopamine Transmission.J Am Acad Child Adolesc Psychiatry 2003;42(8):902-907.
De Wildt SN, De Hoog M, Vinks AA, Van Der Giesen E, Van Den Anker JN. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.Crit Care Med 2003;31(7):1952-8
.
de Hoog M, Schoemaker R, van den Anker JN, Vinks AA. NONMEM and NPEM2 population modeling: A study using tobramycin data from neonates.Ther Drug Monit, 2002;24(3):359-65.
Vinks AA. The application of population pharmacokinetic modeling to individualized antibiotic therapy.Int J Antimicrob Agents. 2002;19(4):313-22.
Mouton JW, Touw DJ, Horrevorts AM, Vinks AA. Comparative pharmacokinetics of the carbapenems: clinical implications.Clin Pharmacokinet 2000;39:185-201.
Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ. Pharmacodynamic evaluation of Once-Daily Dosing in adult Cystic Fibrosis patients.Antimicrob Agents Chemother 2000;44:809-13.
Le Brun PPH, de Graaf AI, Vinks AA. A high-performance liquid chromatographic determination of colistin in serum.Ther Drug Monit. 2000 Oct;22(5):589-93.
Ververs TF, van Dijk A, Vinks AA, Blankestijn PJ, Savelkoul JF, Meulenbelt J, Boereboom FT. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.Crit Care Med. 2000 Oct;28(10):3412-6.
Professional Organization Memberships
- Royal Dutch Pharmacy Society
- Dutch Society of Hospital Pharmacists
- Dutch Society for Clinical Pharmacology and Bio-Pharmacy
- Dutch Society for Toxicology
- International Association for Therapeutic Drug Monitoring and Clinical Toxicology.
- The American Society for Microbiology
- International Society of Antimicrobial Pharmacology
- American College of Clinical Pharmacy
- Ohio College of Clinical Pharmacy
- American College of Clinical Pharmacology
- American Society of Clinical Pharmacology and Therapeutics
Presentations
Invited speaker, TDM 2000: Critical Issues of Drug Level Determinations. Pharmacoeconomics: The role of therapeutic drug monitoring, challenges and opportunities in the new millennium. Basel, Switzerland, February 24, 2000.
Invited speaker, Congress for Laboratory Medicine 2000. Rationale for monitoring of aminoglycosides: Cost-effectiveness of a goal-oriented model-based dosing method. Dÿsseldorf, Germany, November 20-22, 2000.
Invited speaker, Symposium Clinical Pharmacology Topics in Neonatology. Pharmacokinetic-pharmacodynamic optimization of dosing of drugs in neonates. Sophia Children's Hospital, Rotterdam, June 8, 2000.
Presenter, International Association for Therapeutic Drug Monitoring and Clinical Toxicology, PK-PD modeling of Acetaminophen antipyresis in children with fever. September 1-6, 2001, Washington, DC.
Invited faculty and speaker, Workshop, 7th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Issues in pharmacokinetic and pharmacodynamic (PK-PD) data analysis and population modeling. Optimal Experimental Design: When to get Serum Levels. September 2, 2001, Washington, DC.
Invited faculty and speaker, Post-congress workshop 7th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Parametric and nonparametric population PK and PD modeling: Application to multiple model dosage design and optimal sequential Bayesian feedback. September 7-8, 2001, Washington, DC,
Invited speaker, Rainbow Babies Hospital, University Hospitals of Cleveland, Cleveland, OH, November 29-30, 2001. Population modeling and Bayesian adaptive control: applications of goal-oriented model-based principles in TDM and clinical trial design.
Invited speaker, Department of Pharmacology, University of Toronto, Application of Population PK-PD Modeling in pediatric Clinical Trials. Toronto, Canada, April 3-5, 2002.
Invited speaker, IIR Pharmaceuticals. Partnerships in Clinical Trials through fast and effective outsourcing. Designing and conduction Pharmacokinetic trials in pediatric populations. Amsterdam, The Netherlands, May 27-29, 2002.
Invited speaker, Barnett International. Pediatric Clinical Trials. Examining population PK/PD modeling and sparse sampling strategies in pediatric clinical trial design with specific reference to outsourcing of studies. Philadelphia, PA, September 18-20, 2002.
Visiting professor. Dept. of Pathology and Laboratory Medicine. University of Pennsylvania Medical Center. Population modeling of immunosuppressants in pediatrics: toward goal-oriented model-based methods. Philadelphia, PA, September 20, 2002
Invited faculty. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Meet the Expert: Is Therapeutic Drug Monitoring Useful? How should we Do it?, San Diego, CA, September 27-30, 2002.
Invited speaker, Osaka University of Pharmaceutical Sciences, Population modeling and Bayesian adaptive control: applications of goal-oriented model-based principles in TDM and clinical trial design. Osaka, Japan, October 22-25, 2002.
Invited speaker, Shionogi building, Kitasato University, Application of population modeling and Bayesian adaptive control in the optimization of antibiotic therapy. Tokyo, Japan, October 22, 2002.
Invited speaker, Osaka Medical College Hospital, Osaka, Population modeling and Bayesian adaptive control: applications of goal-oriented model-based principles in TDM and clinical trial design. Japan, October 23, 2002.
Invited speaker, Osaka University of Pharmaceutical Sciences, Use of sparse data in Population modeling and TDM adaptive control strategies. Osaka, Japan, October 24, 2002.
Invited speaker, IA-TDM/CT TDM/TOX Workshop. Asian Medical Center, TDM, NONMEM & NPEM: Application of population modeling to the analysis of (sparse) data. Seoul, Korea, October 26, 2002.
Invited speaker, ASCPT Congress, THE workshop – Therapeutic Drug and Toxicology Monitoring is Affected by Age/Gender Difference, Interpretation of Pediatric TDM Findings. Washington DC, April 2-5, 2003.
Invited speaker. American Association of Clinical Chemistry (AACC) Annual Meeting. EduTrak session: Overcoming Barriers to TDM: Informatics and the TDM Renaissance, Barriers to TDM: How to get good clinical data from the hospital IS. Philadelphia, PA, July 23, 2003.
Invited faculty. Antibiotics Pharmacodynamic Modeling Workshop, Leiden University Medical Center, Predictive value of antibiotic PK-PD models, Leiden, The Netherlands, September 4-5, 2003.
Invited faculty and speaker. 8th International Congress on Therapeutic Drug Monitoring & Clinical Toxicology. Workshop: Clinical Pharmacokinetics and TDM - practical problems and solutions.Optimal PK sampling design: when to best get serum levels for TDM and population PK-PD modeling (risperidone and lamotrigine). Basel, Switzerland, September 7-11, 2003
Invited faculty and speaker. 8th International Congress on Therapeutic Drug Monitoring & Clinical Toxicology. Workshop: Applications of Population Modeling to TDM Data, Parametric and nonparametric data analysis: controversial issues in the modeling of sparse sampling. Basel, Switzerland, September 7-11, 2003.
Invited faculty and speaker. Post-congress workshop IATDM-CT Congress, Parametric and nonparametric population PK and PD modeling: Application to multiple model dosage design and optimal sequential Bayesian feedback. Basel, Switzerland, September 12-13, 2003.
Invited expert. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Meet the Expert: Is Therapeutic Drug Monitoring Useful? How should we Do it? Chicago, IL, September 14-17, 2003.
Invited speaker. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Session: The Use of Population Pharmacokinetics in Drug Development and Clinical Practice, Population pharmacokinetics in special populations: special needs? Chicago, IL, September 14-17, 2003.
Invited speaker, Texas Children's Hospital, Baylor College of Medicine, Informatics and the TDM Renaissance: How to integrate PK intelligence with routine clinical data. Houston, TX. October 29-30, 2003.
Invited speaker, Department of Pathology and Laboratory Medicine, University of Louisville Health Sciences Center, Application of population pharmacokinetic models to routine clinical data – From passive monitoring toward active management. Louisville, KY. January 22, 2004.
Visiting professor, "Population Modeling and Clinical Trial Design in Children", Center for Drug Development Research, Georgetown University, Washington, DC, April 21, 2004.
Invited speaker. "Clinical applications of population pharmacokinetic modeling." Proceedings 8th World Congress on Clinical Pharmacology & Therapeutics. Brisbane, Australia, August 1-6, 2004.
Invited expert. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Meet the Expert: "How useful is Therapeutic Drug Monitoring?" Washington, DC, October 30 - November 2, 2004.
Invited expert. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Meet the Expert: "Concentration dependent and time dependent antimicrobial effect: relationship between MIC, killing curves, dosing and effect". Washington, DC, October 30 - November 2, 2004.
Invited speaker. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Workshop ISAP: 'Population PK-PD Modeling of anti-infective agents" Washington, DC, October 30 - November 2, 2004.
Invited speaker. "Pharmacokinetics and Pharmacogenetics of Risperidone in Children with PDD". Mini-Symposium: Gene-drug interactions relevant to psychiatric diseases, Center for Environmental Genetics, University of Cincinnati, February 18, 2005.
Invited speaker/faculty. 8th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology. Workshop: Interpreting Drug Assay Results and Advising on Dosage Alterations using Clinical Pharmacokinetic Software. Louisville, KY, April 23-28, 2005.
Invited speaker/faculty. Post-congress workshop 8th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology. New Advances in Therapeutic Drug Monitoring and Individualized Drug Therapy. Louisville, KY, April 29-30, 2005.
Invited speaker. East meets West - 0th International Congress of Pediatric Laboratory medicine(ICPLM): Pharmacogenomis"Using Pharmacogenetic Data for Dose Individualization in Pediatrics" Singapore, Malaysia, September 3-6, 2005.
Invited speaker. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Pre-meeting Workshop ISAP: 'Population PK-PD Modeling of anti-infective agents" Washington, DC, December 16-19, 2005.
Invited expert. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Meet the Expert: "Patients on dialysis: Modifying treatment Based on Pharmacodynamics" Washington, DC, December 16-19, 2005.
Invited expert. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Meet the Expert: "How useful is Therapeutic Drug Monitoring?" New Orleans, LA, September 23, 2005.
Invited speaker. Johnson & Johnson Pharmaceutical Research & Development Pediatrics Symposium: Pediatric Drug Development: Application of Modeling & Simulation. "Application of disease progress modeling in pediatrics" Raritan, NJ, October 15, 2005.
Book Chapters, Reviews, Invited Papers:
Touw DJ, Mouton JW, Vinks AA, Horrevorts AM, Heijerman HGM. Antibiotic treatment in cystic fibrosis. Part 1: Introduction. Clinical pharmacokinetics and toxicology. Antimicrobics and Infectious Disease Newsletter. 2000;18(4):25-29.
Mouton JW, Touw DJ, Vinks AA, Horrevorts AM, Heijerman HGM. Antibiotic treatment in cystic fibrosis. Part 2: Dose optimization. Antimicrobics and Infectious Disease Newsletter. 2000;18 (5):33-37.
Vinks AA. Pharmacokinetic Monitoring of Aminoglycosides in the Extended Dosing Interval Era. J Lab Med 2002; 26(1/2):43-48.
Vinks AA, Walson PD. Chapter 4: Pharmacokinetics I: Developmental Principles. In: Martin A, Scahill L, Charney D, Leckman J, Editors. Pediatric Psychopharmacology: Principles and Practice. New York: Oxford University Press; 2003. p. 44-53.
Vinks AA, Walson PD. Chapter 9: Therapeutic Drug Monitoring. In: Neonatal and Pediatric Pharmacology, 3rd Edition, Eds. Yaffe S J, Aranda JV. Lippincott Williams & Wilkins; 2005. p. 99-110.
Related Areas
This person works in these other areas at Cincinnati Children's Hospital Medical Center:
